James T Parsons1, Bruce D Greene2. 1. South Florida Radiation Oncology, Boynton Beach, Florida. Electronic address: jtparsons007@yahoo.com. 2. Valley View Hospital, Glenwood Springs, Colorado.
Abstract
PURPOSE: To review radiation fractionation and chemotherapy trials for patients undergoing organ preservation therapy for locally advanced head and neck squamous cell carcinoma. METHODS AND MATERIALS: Radiation therapy fractionation and chemotherapy trial results as well as historical evidence are systematically reviewed. RESULTS: Trial results, which involve nearly 30,000 patients, have been interpreted, compared, and presented in a structured manner to demonstrate the changing approaches in treatment over the years from the 1960s to the present. The review includes data from the split-course radiation therapy era, meta-analyses of chemotherapy and radiation therapy fractionation trials, cetuximab trials, "triple-drug trials," and modern trials of induction chemotherapy followed by concomitant chemotherapy and radiation therapy. CONCLUSIONS: This summary will be useful to clinicians making treatment decisions today and to investigators designing trials in the future.
PURPOSE: To review radiation fractionation and chemotherapy trials for patients undergoing organ preservation therapy for locally advanced head and neck squamous cell carcinoma. METHODS AND MATERIALS: Radiation therapy fractionation and chemotherapy trial results as well as historical evidence are systematically reviewed. RESULTS: Trial results, which involve nearly 30,000 patients, have been interpreted, compared, and presented in a structured manner to demonstrate the changing approaches in treatment over the years from the 1960s to the present. The review includes data from the split-course radiation therapy era, meta-analyses of chemotherapy and radiation therapy fractionation trials, cetuximab trials, "triple-drug trials," and modern trials of induction chemotherapy followed by concomitant chemotherapy and radiation therapy. CONCLUSIONS: This summary will be useful to clinicians making treatment decisions today and to investigators designing trials in the future.
Authors: Olgun Elicin; Paul Martin Putora; Marco Siano; Martina A Broglie; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Pavel Dulguerov; Guido Henke Journal: Front Oncol Date: 2019-10-24 Impact factor: 6.244